News
Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023
ROCKVILLE, Md., Jan. 17, 2023 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that...
Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants
ROCKVILLE, Md., Jan. 12, 2023 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side...
Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications
ROCKVILLE, Md., Jan. 10, 2023 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the...
Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications
ROCKVILLE, Md., Dec. 6, 2022 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the...
Shuttle Pharmaceuticals Provides Third Quarter 2022 Corporate Update
ROCKVILLE, Md., Nov. 15, 2022 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today provided a...
Shuttle Pharmaceuticals Engages Theradex Oncology in Preparation for Clinical Study
ROCKVILLE, Md., Nov. 3, 2022 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing its side...
Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors
ROCKVILLE, Md., Nov. 1, 2022 --Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the...
Shuttle Pharmaceuticals Enters into Manufacturing Agreement for Ropidoxuridine
Agreement to help advance lead clinical sensitizer drug candidate ROCKVILLE, Md., Sept. 20, 2022 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer...
Shuttle Pharmaceuticals Awarded New HDAC Inhibitor Patents for Cancer Treatment
Company awarded patents in the U.S. and Hong Kong ROCKVILLE, Md., Sept. 15, 2022 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company, announced today that it has been awarded patents in the U.S....
Shuttle Pharmaceuticals Announces Closing of Initial Public Offering
ROCKVILLE, Md., Sept. 6, 2022 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side...